Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Q1 2023 Earnings Conference Call May 3, 2023 8:00 AM ET
Company Participants
Todd Tushla - VP, IR
Kevin Gorman - CEO
Matt Abernethy - CFO
Eric Benevich - Chief Commercial Officer
Eiry Roberts - Chief Medical Officer
Kyle Gano - Chief Business Development & Strategy Officer
Conference Call Participants
Philip Nadeau - Cowen & Company
Tazeen Ahmad - Bank of America
Paul Matteis - Stifel
Josh Schimmer - Evercore
Neena Bitritto-Garg - Citi
Chris Shibutani - Goldman Sachs
Brian Abrahams - RBC Capital Markets
Anupam Rama - JPMorgan
Carter Gould - Barclays
Myles Minter - William Blair
Marc Goodman - SVB Securities
Brian Skorney - Baird
Danielle Brill - Raymond James
Jay Olson - Oppenheimer
Laura Chico - Wedbush Securities
Sumant Kulkarni - Canaccord Genuity
David Amsellem - Piper Sandler
Akash Tewari - Jefferies
Ashwani Verma - UBS
Yatin Suneja - Guggenheim Partners
Uy Ear - Mizuho Securities
Ami Fadia - Needham
Operator
Good day, everyone, and welcome to the Neurocrine Biosciences Reports First Quarter Results. At this time, all participants are in a listen-only mode. Later, you will have the opportunity to ask questions during the question-and-answer session. [Operator Instructions] Please note this call may be recorded and I will be standing by should you need any assistance.
It is now my pleasure to turn the call over to Todd Tushla, Vice President of Investor Relations. Please go ahead.
Todd Tushla
Thank you, operator, and good morning, everyone. Welcome to Neurocrine's first quarter 2023 earnings call. This morning, I’m joined by Kevin Gorman, our Chief Executive Officer; Matt Abernethy, our Chief Financial Officer; Eiry Roberts, our Chief Medical Officer; Eric Benevich, our Chief Commercial Officer; and Kyle Gano, our Chief Business Development and Strategy Officer.
I’ll remind everyone that during today’s call, we will be making forward-looking statements. These statements are subject to certain risks and uncertainties, and our actual results may differ materially. I encourage you to review the risk factors discussed in our latest SEC filings. After our prepared remarks, we will once again do our best to address all of your questions.
And now, I'll hand the call over to Kevin Gorman.
Kevin Gorman
Thank you, Todd, and good morning. Well, INGREZZA has had yet another very good quarter of sales. And I say this from a dollar perspective, but more importantly, the fundamentals of bringing INGREZZA to patients is even stronger with more new prescriptions than ever and remarkably to me, this occurred in Q1 typically our toughest quarter because of insurance reauthorizations.